XML 25 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative effect, period of adoption, adjustment
Common Stock
Capital in Excess of Par Value
Retained Earnings
Retained Earnings
Cumulative effect, period of adoption, adjustment
Treasury Stock
Accumulated Other Comprehensive Income (Loss)
Total Synopsys Stockholders’ Equity
Total Synopsys Stockholders’ Equity
Cumulative effect, period of adoption, adjustment
Non-controlling Interest
Balance (in shares) at Oct. 31, 2017     150,445                
Beginning balance at Oct. 31, 2017 $ 3,279,724   $ 1,505 $ 1,622,429 $ 2,143,873   $ (426,208) $ (65,979) $ 3,275,620   $ 4,104
Beginning balance (Adjustment related to reclassification of certain tax effects from accumulated other comprehensive income (loss)) at Oct. 31, 2017   $ (293)       $ (293)       $ (293)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 432,518       432,518       432,518    
Other comprehensive income (loss), net of tax effects $ (47,198)             (47,198) (47,198)    
Purchases of treasury stock (in shares) (4,688) [1]   (4,688)                
Purchases of treasury stock, value $ (420,000) [1]   $ (47) 47     (420,000)   (420,000)    
Equity forward contract $ 20,000     20,000         20,000    
Common stock issued, net of shares withheld for employee taxes (in shares) 3,508   3,508                
Common stock issued, net of shares withheld for employee taxes $ 79,629   $ 35 (136,522) (32,410)   248,526   79,629    
Stock-based compensation 138,876     138,876         138,876    
Non-controlling interest in an equity investment 1,759             0   1,759
Balance (in shares) at Oct. 31, 2018     149,265                
Ending balance at Oct. 31, 2018 3,485,015   $ 1,493 1,644,830 2,543,688   (597,682) (113,177) 3,479,152   5,863
Ending balance (Adjustment due to adoption of accounting standards related to revenue) at Oct. 31, 2018   257,594       257,594       257,594  
Ending balance (Adjustment due to adoption of an accounting standard related to income taxes) at Oct. 31, 2018   $ (130,544)       $ (130,544)       $ (130,544)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 532,367       532,367       532,367    
Other comprehensive income (loss), net of tax effects $ 20,730             20,730 20,730    
Purchases of treasury stock (in shares) (2,732)   (2,732)                
Purchases of treasury stock, value $ (329,185)   $ (27) 27     (329,185)   (329,185)    
Common stock issued, net of shares withheld for employee taxes (in shares) 3,798   3,798                
Common stock issued, net of shares withheld for employee taxes $ 99,103   $ 37 (163,198) (38,961)   301,225   99,103    
Stock-based compensation 153,796     153,796         153,796    
Balance (in shares) at Oct. 31, 2019     150,331                
Ending balance at Oct. 31, 2019 4,088,876   $ 1,503 1,635,455 3,164,144   (625,642) (92,447) 4,083,013   5,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income 663,447       664,347       664,347   (900)
Other comprehensive income (loss), net of tax effects $ 38,373             38,373 38,373    
Purchases of treasury stock (in shares) (1,585)   (1,585)                
Purchases of treasury stock, value $ (242,078)   $ (14) 14     (242,078)   (242,078)    
Common stock issued, net of shares withheld for employee taxes (in shares) 3,872   3,872                
Common stock issued, net of shares withheld for employee taxes $ 115,165   $ 39 (230,887) (33,094)   379,107   115,165    
Stock-based compensation 248,584     248,584         248,584    
Balance (in shares) at Oct. 31, 2020     152,618                
Ending balance at Oct. 31, 2020 $ 4,912,367   $ 1,528 $ 1,653,166 $ 3,795,397   $ (488,613) $ (54,074) $ 4,907,404   $ 4,963
[1]
The first quarter of fiscal 2018 includes the settlement of the $20.0 million equity forward contract related to the September 2017 ASR.